- Home
- ZDAI vs KZIA Comparison
ZDAI vs KZIA Comparison
Compare ZDAI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDAI
- KZIA
- Stock Information
- Founded
- ZDAI 2022
- KZIA 1994
- Country
- ZDAI Hong Kong
- KZIA Australia
- Employees
- ZDAI N/A
- KZIA N/A
- Industry
- ZDAI General Bldg Contractors - Nonresidential Bldgs
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- ZDAI Consumer Discretionary
- KZIA Health Care
- Exchange
- ZDAI Nasdaq
- KZIA Nasdaq
- Market Cap
- ZDAI 13.5M
- KZIA 11.7M
- IPO Year
- ZDAI 2024
- KZIA 1999
- Fundamental
- Price
- ZDAI $0.53
- KZIA $8.04
- Analyst Decision
- ZDAI
- KZIA Strong Buy
- Analyst Count
- ZDAI 0
- KZIA 2
- Target Price
- ZDAI N/A
- KZIA $14.00
- AVG Volume (30 Days)
- ZDAI 69.7K
- KZIA 70.7K
- Earning Date
- ZDAI 08-29-2025
- KZIA 08-26-2025
- Dividend Yield
- ZDAI N/A
- KZIA N/A
- EPS Growth
- ZDAI N/A
- KZIA N/A
- EPS
- ZDAI N/A
- KZIA N/A
- Revenue
- ZDAI $19,275,673.00
- KZIA $1,549,158.00
- Revenue This Year
- ZDAI N/A
- KZIA N/A
- Revenue Next Year
- ZDAI N/A
- KZIA $49.25
- P/E Ratio
- ZDAI N/A
- KZIA N/A
- Revenue Growth
- ZDAI 56.11
- KZIA 248983.08
- 52 Week Low
- ZDAI $0.37
- KZIA $2.86
- 52 Week High
- ZDAI $107.36
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- ZDAI N/A
- KZIA 44.85
- Support Level
- ZDAI N/A
- KZIA $7.58
- Resistance Level
- ZDAI N/A
- KZIA $8.88
- Average True Range (ATR)
- ZDAI 0.00
- KZIA 0.58
- MACD
- ZDAI 0.00
- KZIA -0.14
- Stochastic Oscillator
- ZDAI 0.00
- KZIA 39.94
About ZDAI Primega Group Holdings Limited Ordinary Shares
Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.